Value-based care and early palliative care are strategies to mitigate rising cancer treatment costs due to longer patient ...
The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...
2d
FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression
The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on ...
The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.
Pharmaceutical Technology on MSN
J&J’s Darzalex gains first FDA approval in smouldering multiple myeloma
This approval marks a milestone for high-risk sMM patients, but analyst Biswajit Podder notes that there are caveats to its ...
Kimberly Alexander's caregiving experience revealed a lack of awareness and support for multiple myeloma, especially in the ...
Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...
The FDA has approved daratumumab and hyaluronidase (DARA SC; Darzalex Faspro, Janssen Biotech) for adults with high-risk smoldering multiple myeloma (SMM). The approval makes DARA SC, a subcutaneous ...
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...
A new option is now approved to treat adults living with high-risk smoldering multiple myeloma (MM). 1 The FDA has greenlit ...
The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in patients with high-risk ...
The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback